Key result
Fenofibrate cessation during in vitro fertilization triggers severe hypertriglyceridemia-induced pancreatitis.
Why the study?
Management of hypertriglyceridemia in women undergoing IVF is challenging due to concerns about fenofibrate teratogenicity and risk of pancreatitis.
Case Report (n=1)
May warrant caution stopping fenofibrate before IVF in prior pancreatitis patients; leaves open optimal lipid management strategies.
A 36-year-old woman with prior hypertriglyceridemia-induced pancreatitis presented with a recurrence of pancreatitis after beginning in vitro fertilization (IVF). Her primary care physician had discontinued fenofibrate due to concerns for teratogenicity. This case illustrates the importance of fibrate therapy for high-risk women undergoing IVF, despite limited evidence regarding its teratogenicity.
No takes yet. Share an insight, caveat, or question.
Shrimanker et al. (2022) conducted a case report in Hypertriglyceridemia-induced pancreatitis (n=1). Fenofibrate cessation and in vitro fertilization was evaluated. Fenofibrate cessation combined with in vitro fertilization triggered a recurrence of severe hypertriglyceridemia-induced pancreatitis (triglycerides 3,296 mg/dl) in a 36-year-old woman.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: